Published in Infect Immun on April 01, 2006
IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med (2008) 9.05
Th17 cells in human disease. Immunol Rev (2008) 4.27
Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog (2008) 4.05
In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med (2008) 3.85
Th17 cells and mucosal host defense. Semin Immunol (2007) 3.17
Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest (2009) 3.16
Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol (2009) 3.01
Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog (2009) 2.69
Precarious balance: Th17 cells in host defense. Infect Immun (2009) 1.60
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol (2008) 1.42
Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun (2008) 1.39
Reduced memory CD4+ T-cell generation in the circulation of young children may contribute to the otitis-prone condition. J Infect Dis (2011) 1.30
Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev (2014) 1.28
The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA. Immunol Rev (2012) 1.23
Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol (2009) 1.18
CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J Immunol (2010) 1.17
The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol (2010) 1.17
Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun (2009) 1.13
Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci U S A (2012) 1.09
Th17 cytokines and vaccine-induced immunity. Semin Immunopathol (2010) 1.07
Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country. Vaccine (2012) 1.07
Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. Clin Exp Immunol (2009) 1.05
GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine (2010) 1.03
Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci U S A (2013) 1.01
Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adults. PLoS One (2011) 1.00
Defective pneumococcal-specific Th1 responses in HIV-infected adults precedes a loss of control of pneumococcal colonization. Clin Infect Dis (2012) 1.00
T cell-mediated host immune defenses in the lung. Annu Rev Immunol (2013) 1.00
Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol (2010) 0.99
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One (2010) 0.98
Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol (2010) 0.97
The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine (2009) 0.97
Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog (2012) 0.97
Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol (2013) 0.95
Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans. Clin Vaccine Immunol (2011) 0.94
Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol (2009) 0.93
Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization. Infect Immun (2010) 0.92
Cellular immune response in young children accounts for recurrent acute otitis media. Curr Allergy Asthma Rep (2013) 0.90
Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection. Am J Pathol (2013) 0.90
Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation. Immunity (2016) 0.90
Immune responses to gut microbiota-commensals and pathogens. Gut Microbes (2010) 0.89
CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine (2013) 0.88
T helper 17-associated cytokines are produced during antigen-specific inflammation in the mammary gland. PLoS One (2013) 0.88
Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol (2011) 0.87
Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One (2010) 0.85
Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice. Infect Immun (2011) 0.85
Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy. Sci Rep (2015) 0.85
Mouse models for the study of mucosal vaccination against otitis media. Vaccine (2008) 0.83
Prostaglandin E2-dependent IL-23 production in aged murine dendritic cells. Exp Gerontol (2010) 0.83
Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides. PLoS One (2008) 0.83
Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol (2009) 0.82
Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog (2009) 0.82
Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice. Clin Vaccine Immunol (2012) 0.81
Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunol (2016) 0.81
A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi. Vaccine (2012) 0.81
Harnessing the Therapeutic Potential of Th17 Cells. Mediators Inflamm (2015) 0.80
CD4(+) T-cell subsets and host defense in the lung. Immunol Rev (2013) 0.79
Transcriptome profiling reveals Th17-like immune responses induced in zebrafish bath-vaccinated with a live attenuated Vibrio anguillarum. PLoS One (2013) 0.79
Application of radiation technology in vaccines development. Clin Exp Vaccine Res (2015) 0.78
Interleukin-22 mediates early host defense against Rhizomucor pusilluscan pathogens. PLoS One (2013) 0.77
The Pneumococcal Alpha-Glycerophosphate Oxidase Enhances Nasopharyngeal Colonization through Binding to Host Glycoconjugates. EBioMedicine (2017) 0.75
Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology (2014) 0.75
Interluekin-17A (IL17A). Gene (2017) 0.75
Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice. J Leukoc Biol (2017) 0.75
Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. Immunol Lett (2014) 0.75
A combination of recombinant BCG expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis. Clin Vaccine Immunol (2017) 0.75
A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice. Vaccine (2017) 0.75
Reduced Th17 responses to Streptococcus pneumoniae in infection-prone children can be rescued by addition of innate cytokines. J Infect Dis (2017) 0.75
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 13.19
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med (1981) 6.45
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun (1994) 4.90
Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol (2001) 4.56
Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis (1998) 4.12
Pneumococcal C-substance, a ribitol teichoic acid containing choline phosphate. Biochem J (1968) 3.94
IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol (2004) 3.84
Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics (2004) 3.71
Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis (2004) 3.43
CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A (2005) 3.30
The immune response to pneumococcal proteins during experimental human carriage. J Exp Med (2002) 3.03
Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis (1996) 2.96
Cross-reactions between pneumococci and other streptococci due to C polysaccharide and F antigen. J Clin Microbiol (1987) 2.93
Polysaccharide processing and presentation by the MHCII pathway. Cell (2004) 2.88
Pathogenesis of pneumococcal infection. N Engl J Med (1995) 2.87
CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol (2003) 2.79
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun (1996) 2.64
Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun (2004) 2.53
Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol (2003) 2.50
Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis (2003) 2.46
Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun (2004) 2.38
Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun (2001) 2.19
Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A (1993) 2.18
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol (2005) 2.03
Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med (2005) 1.97
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine (2000) 1.82
Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis (1990) 1.72
Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun (2001) 1.71
CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun (2004) 1.70
Capsulation of pneumococcus with soluble C-like (Cs) polysaccharide. I. Biological and genetic properties of Cs pneumococcal strains. J Exp Med (1968) 1.65
Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec (1999) 1.63
T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem (2000) 1.57
Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect Immun (2003) 1.51
The inhibitory effect of C-reactive protein on bacterial phosphorylcholine platelet-activating factor receptor-mediated adherence is blocked by surfactant. J Infect Dis (2002) 1.49
Nature of the cross-protective antigen in subcellular vaccines of Streptococcus pneumoniae. Infect Immun (1981) 1.43
Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect Immun (1988) 1.42
Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun (1986) 1.30
Phase variation in colony opacity by Streptococcus pneumoniae. Microb Drug Resist (1998) 1.30
Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J Immunol (1983) 1.27
Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect Immun (1994) 1.20
Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun (2004) 1.18
The pneumococcal common antigen C-polysaccharide occurs in different forms. Mono-substituted or di-substituted with phosphocholine. Eur J Biochem (1999) 1.16
Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis (2004) 1.15
Antibodies against pneumococcal C-polysaccharide are not protective. Microb Pathog (1993) 1.15
The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine (1997) 1.11
Can nonliving nasal vaccines be made to work? Expert Rev Vaccines (2002) 0.87
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun (1999) 0.86
Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae. Vaccine (2000) 0.81
Transmissibility of 1918 pandemic influenza. Nature (2004) 16.14
Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? J Infect Dis (2008) 7.76
Serotype replacement in disease after pneumococcal vaccination. Lancet (2011) 7.14
Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proc Natl Acad Sci U S A (2007) 5.90
The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med (2009) 5.86
Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg Infect Dis (2009) 5.56
Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS Biol (2010) 5.43
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol (2006) 4.58
Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A (2003) 4.56
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet (2011) 4.19
Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog (2008) 4.05
Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza Other Respir Viruses (2009) 4.02
Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med (2003) 3.54
Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A (2004) 3.46
Genomic epidemiology of the Escherichia coli O104:H4 outbreaks in Europe, 2011. Proc Natl Acad Sci U S A (2012) 3.42
Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics (2009) 3.32
CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A (2005) 3.30
Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis (2010) 3.29
Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia I. Patterns of lagged weather effects reflect biological mechanisms. Malar J (2004) 3.07
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med (2008) 3.00
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis (2002) 2.99
Pandemic flu: we are not prepared. MedGenMed (2005) 2.89
Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol (2006) 2.81
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet (2013) 2.80
Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog (2009) 2.69
Improving the estimation of influenza-related mortality over a seasonal baseline. Epidemiology (2012) 2.68
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis (2010) 2.50
Real-time influenza forecasts during the 2012-2013 season. Nat Commun (2013) 2.26
Interference between Streptococcus pneumoniae and Staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. J Bacteriol (2006) 2.22
Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. PLoS Med (2011) 2.22
Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4. Appl Environ Microbiol (2003) 2.19
Proximal femoral nails compared with reverse distal femoral locking plates in intertrochanteric fractures with a compromised lateral wall; a randomised controlled trial. Int Orthop (2014) 2.15
Generation interval contraction and epidemic data analysis. Math Biosci (2008) 2.04
Absolute humidity and pandemic versus epidemic influenza. Am J Epidemiol (2010) 2.00
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A (2006) 2.00
Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis (2006) 1.99
Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med (2009) 1.99
Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis (2011) 1.95
Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci U S A (2009) 1.92
Modeling community- and individual-level effects of child-care center attendance on pneumococcal carriage. Clin Infect Dis (2005) 1.91
Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis (2004) 1.90
The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun (2005) 1.86
Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med (2010) 1.83
Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J Infect Dis (2008) 1.72
Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS (2012) 1.71
Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J Clin Microbiol (2007) 1.68
Antibiotic resistance--the interplay between antibiotic use in animals and human beings. Lancet Infect Dis (2003) 1.67
Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis (2005) 1.61
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol (2006) 1.58
Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". Science (2012) 1.58
Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis (2011) 1.51
Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol (2007) 1.51
The analysis of hospital infection data using hidden Markov models. Biostatistics (2004) 1.51
Vaccine production, distribution, access, and uptake. Lancet (2011) 1.49
SpxB is a suicide gene of Streptococcus pneumoniae and confers a selective advantage in an in vivo competitive colonization model. J Bacteriol (2007) 1.48
Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae. J Bacteriol (2004) 1.48
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res (2010) 1.45
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis (2007) 1.43
Alert threshold algorithms and malaria epidemic detection. Emerg Infect Dis (2004) 1.42
Leprosy and the adaptation of human toll-like receptor 1. PLoS Pathog (2010) 1.41
Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J (2012) 1.41
Incremental increase in fitness cost with increased beta -lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J Infect Dis (2006) 1.40
Pulseless right groin… bounding distal pulses. J Invasive Cardiol (2011) 1.39
Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69). J Cell Mol Med (2010) 1.39
Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science (2012) 1.39
Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun (2008) 1.39
Quantifying interhospital patient sharing as a mechanism for infectious disease spread. Infect Control Hosp Epidemiol (2010) 1.39
Student behavior during a school closure caused by pandemic influenza A/H1N1. PLoS One (2010) 1.38
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine (2010) 1.37
Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect Immun (2009) 1.35
Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun (2005) 1.35
The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS One (2012) 1.34
Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol (2005) 1.31
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? J R Soc Interface (2009) 1.30
Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. Pediatr Infect Dis J (2011) 1.28
Pandemic influenza: risk of multiple introductions and the need to prepare for them. PLoS Med (2006) 1.26
Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol (2010) 1.25